Clinical Trials for Low-Grade Serous Ovarian cancer
Clinical studies are a type of research for which people with low-grade serous ovarian cancer and low-grade serous peritoneal cancer can volunteer. They help doctors gain a better understanding of how to treat low-grade serous ovarian cancer (LGSOC).
Clinical studies include clinical trials and observational studies. They can be for newly diagnosed, recurrence or any point from diagnosis.
On this page:
Types of clinical studies
Clinical studies include clinical trials and observational studies. Both types of clinical research are important as they help improve future prevention, diagnosis, survival and quality of life of people with low-grade serous ovarian cancer.
Clinical trials
Clinical trials are a type of interventional research. There are various types of clinical trials and your participation in a clinical trial could alter your treatment.
Phase 1 clinical trials aim to determine the best dose, identify side effects, and assess how well a new drug treats the cancer.
Phase 2 clinical trials focus on learning more about the optimal dose, side effects, and the drug’s effectiveness in treating the cancer.
Phase 3 clinical trials evaluate whether the new treatment works better than existing treatments.
Observational studies
Observational studies collect data on people over time to see what happens to them. Taking part in an observational study does not change your treatment.
Risks and benefits of participating in clinical trials
Potential benefits of participating in a clinical trial could include:
- Accessing new treatments
- Close monitoring by your medical team
- Contributing to a greater understanding of your cancer
Potential risks of participating in a clinical trial could include:
- Side effects
- New tests or treatments may not work
- More hospital visits
Modified from the NCCN Guidelines
Ways to find a clinical trial
If you are interested in taking part in clinical research you can:
- Talk to your doctor
- Search a clinical trials database
- Review our list of low-grade serous ovarian cancer clinical trials
- If your country does not have a low-grade serous ovarian cancer-specific study that you can participate in, there may still be multi-cancer trials available.
Clinical trial databases
- ClinicalTrials.gov a resource provided by the U.S. National Library of Medicine that lists trials across 207 countries.
- International Clinical Trials Registry Platform hosted by the World Health Organisation
- EU Clinical Trials Register lists trials based in the European Union
- Be Part of Research UK for UK-specific trials
- ANZCTR trials database for Australia and New Zealand
- Canadian Cancer Trials
- ISRCTN an international registry of clinical trials
- OCRA Clinical Trials Navigation Service (US only)
Useful search terms
Useful search terms for finding low-grade serous ovarian and peritoneal cancer clinical studies include:
- “low-grade serous”
- “low-grade serous ovarian cancer”
- “low-grade serous carcinoma”
- “low-grade serous adenocarcinoma”
- “LGSOC”
- “LGSC”
LGSOC-specific clinical trials list
See our list below for low-grade serous ovarian cancer clinical trials taking place around the world.
For the most up-to-date information please consult your doctor and a clinical trials database. Trial locations are indicative only and may change over time. Click on a linked trial for more details.
Trials for people newly diagnosed with low-grade serous ovarian cancer
- A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer (CHAMELEON) (US)
- Maintenance Therapy With Aromatase Inhibitor (AI) in Epithelial Ovarian Cancer (MATAO) (People in this study could be randomised to a treatment option of chemotherapy with no maintenance therapy. Findings from a 2022 retrospective study suggest that people who receive AI maintenance therapy may have a reduced risk of recurrence. To help you decide if this study is right for you, you may want to ask your doctor to help you interpret the original research paper in the context of this clinical trial) (Austria, Switzerland)
- Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial) (LEPRE) (People in this study could be randomised to a treatment option of chemotherapy with no maintenance therapy. See comment above.) (Italy)
Trials for people experiencing recurrence/progression of low-grade serous ovarian cancer
- A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer (RAMP 301). Early results from the Phase 2 trial are available here. (US, Canada, UK, Europe, Korea, Australia)
- Study of LY4170156 in Participants With Selected Advanced Solid Tumors (low-grade serous ovarian cancer carcinoma expansion cohort) (Australia, France, Italy, Japan, South Korea, Spain, US)
- Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer (ALEPRO) (Belgium, France, Netherlands)
- Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer (US)
- Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers US
- Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers (US)
- Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial (US) – related to this phase 1 trial which has released results
- Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO) (US)
Observational data collection studies for low-grade serous ovarian cancer
- Data Collection for Patients with Low-Grade Ovarian Carcinoma (MD Anderson, US)
- Observational Retrospective Study on Treatment and Outcomes in Patients With Low-grade Serous Ovarian Cancer (MITO 22) (Italy)
- Cart-Wheel Rare Cancer Database (Australia and New Zealand)
Multi-cancer trials that accept LGSOC patients
In addition to low-grade serous specific trials, some people with low-grade serous carcinoma may also qualify for broader cancer trials that accept many types of cancer, or cancers with specific mutations.
Below are a few examples of some of the types of multi-cancer trials that might accept people with low-grade serous cancer.
- Ovarian cancer trial: A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian Cancer (no longer recruiting: interim results here)
- Mutation specific trial (KRAS G12C): JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
- Multi-cancer trial: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
- Multi-cancer trial targeting folate receptors: A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
- Multi-cancer trial with MEK inhibitor: Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors (China)
The best way to find a multi-cancer trial is to speak to your doctor or search one of the clinical trials databases mentioned earlier on this page.
Useful search terms for multi-cancer trials
- “ovarian cancer”
- “solid tumor” with “ER(+)” or “MEK inhibitor” or “folate receptor”
- the name of any specific genetic mutations identified (e.g. KRAS)
Trials now closed to recruitment
A list of trials previously listed on this page that are no longer recruiting.
- Fulvestrant Plus Abemaciclib in Women With Advanced Low-Grade Serous (recruitment closed 2022 – initial results)
- Multi-cancer trial including MEK inhibitor: Selumetinib and Olaparib in Solid Tumors (recruitment closed)
- Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian or Primary Peritoneal Cancer (Mentioned in this article) (US, Canada, Korea)
- A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients (RAMP201J) (Japan)
- A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation (Belgium, Canada, France, Italy, Spain, UK, US)
- FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study (FUCHSia) (recruitment closed – Belgium)
- Phase I Trial of VS-6063 and RO5126766. (FRAME) (recruitment closed – see updated results) (UK)
- Ribociclib and Letrozole Treatment in Ovarian Cancer (Recruitment closed. Initial results discussed here) (US)
- Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial (US)
- A Study of Onapristone ER in Low Grade Serous Ovarian Cancer
- Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (US and Puerto Rico)
- A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (BOUQUET) (no longer recruiting)
- Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer (PERCEPTION) (Germany) – initial results: https://www.esmoopen.com/article/S2059-7029(26)02127-7/fulltext
- A Study Combining the M3814 Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High-Grade Serous Ovarian Cancer and Low-Grade Serous Ovarian Cancer Patients (Recruitment suspended Nov 2021)
- Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer (TICTOC) (Australia only)
- Phase II basket study of an ARomatase inhibitor plus PI3KCA inhibitor or CDK4/6 inhibitor in women with hormone receptor positive recurrent/metastatic Gynaecological Neoplasms (PARAGON-II) (Australia, New Zealand)
Page updated July 2024